Quantcast

Latest Novartis Stories

2014-06-23 08:29:39

- Initiates Global Footprint, Diversifies Business, Enhances Long-term Growth Prospects - ANAHEIM, Calif., June 23, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the transaction acquiring rights to Synacthen(®) and Synacthen(®) Depot from Novartis Pharma AG and Novartis AG in certain countries outside the U.S. has now closed. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid...

2014-06-19 08:29:24

DUBLIN, June 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of Delaware has found certain claims of United States Patent Nos. 6,335,031 and 6,316,023 valid and infringed by Actavis' generic version of Novartis' Exelon(®) Patch (rivastigmine transdermal system). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal. Exelon(®) Patch is a prescription medicine...

2014-06-18 16:26:18

RESEARCH TRIANGLE PARK, N.C., June 18, 2014 /PRNewswire-USNewswire/ -- The United Nations projects that by 2050, we'll have nine billion people in the world. Those additional 1.8 billion people will need to eat. Where will all that food come from? It's a question that North Carolina companies are researching in earnest. For example, we know we'll need crops that tolerate drought, but will there be new ways of controlling pests and disease? North Carolina has companies working on that. We'll...

2014-06-17 08:29:10

Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US(1) BASEL, Switzerland, June 17, 2014 /PRNewswire/ -- Novartis announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero(®) (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal...

2014-06-16 08:28:43

Cell-culture technology is a modern alternative to manufacture influenza vaccines without chicken eggs, with potential to rapidly respond to a pandemic[1] BASEL, Switzerland, June 16, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) licensed its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccines. This is the first US facility of its kind and is now approved for commercial production. The site will...

2014-06-16 00:21:15

- Access to germplasm, seeds pipeline and commercial varieties BASEL, Switzerland, June 16, 2014 /PRNewswire/ -- Syngenta announced today an agreement to acquire the German and Polish winter wheat and winter oilseed rape (WOSR) breeding and business operations of Lantmannen, the Swedish food, energy and agriculture group. Syngenta will gain access to high-quality germplasm, a seeds pipeline and commercial varieties which complement the company's portfolio in two of Europe's...

2014-06-13 12:22:37

NEW YORK, June 13, 2014 /PRNewswire/ -- PHARMACEUTICAL EXECUTIVE magazine's June cover ranks Pharma's 50 top global pharmaceutical companies by revenues. PHARMACEUTICAL EXECUTIVE'S June issue features the annual review of the top 50 biopharmaceutical companies in industry sales--a standard benchmark of success that has remained surprisingly static since the magazine has began ranking the 50 largest players back in the April 2000 issue. Over these 14 years, just three...

2014-06-13 08:24:31

SCRS Welcomes INC Research, inVentiv Health, Novartis and Sanofi ELLICOTT CITY, Md., June 13, 2014 /PRNewswire/ -- Leading sponsor and CRO organizations continue to join the Society for Clinical Research Sites' (SCRS) Global Impact Partner (GIP) program at a rapid pace. Since April 1, INC Research, inVentiv Health, Novartis and Sanofi have joined the SCRS GIP program. From its inception only one year ago, the initiative has quickly grown to 25 leading organizations. Global Impact...

2014-06-13 08:23:37

DALLAS, June 13, 2014 /PRNewswire/ -- MarketReportsChina.com adds "Research on China Cardiovascular Drugs Industry, 2014-2018" market intelligence report of 85 pages to its store. Delivery of this report will take 24 hours post purchase. Research on China Cardiovascular Drugs Industry, 2014-2018 says in the next ten years, there is a potential for the growth in cardiovascular diseases treatment field. It is predicted that the growth rate will be of more than 20% from...

2014-06-10 08:31:46

- Veteran of animal health brings depth of expertise to Merial's R&D organization - LYON, France, June 10, 2014 /PRNewswire/ -- Merial, the animal health division of Sanofi, today announced that Fabian Kausche will be leading the company's global research and development (R&D) efforts, effective June 9, 2014. Dr. Kausche brings to the company a wide range of global experience in pharmaceutical and biological R&D and business leadership positions, at both human and animal...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.